Transgenic Epidermal Cultures for Junctional Epidermolysis Bullosa — 5-Year Outcomes
Maximilian Kueckelhaus, M.D., Tobias Rothoeft, M.D., Laura De Rosa, Ph.D., Burcu Yeni, B.Sc., Tobias Ohmann, Ph.D., Christoph Maier, M.D., Lynn Eitner, M.D., Dieter Metze, M.D., Lorena Losi, M.D., Ph.D., Alessia Secone Seconetti, Ph.D., Michele De Luca, M.D., and Tobias Hirsch, M.D.
SUMMARY
Inherited junctional epidermolysis bullosa is a severe genetic skin disease that leads to epidermal loss caused by structural and mechanical fragility of the integuments. There is no established cure for junctional epidermolysis bullosa. We previously reported that genetically corrected autologous epidermal cultures regenerated almost an entire, fully functional epidermis on a child who had a devastating form of junctional epidermolysis bullosa. We now report long-term clinical outcomes in this patient. (Funded by POR FESR 2014–2020 — Regione Emilia-Romagna and others.)
N Engl J Med 2021; 385:2264-2270
DOI: 10.1056/NEJMoa2108544
Search
Tag
Recent Posts
- Newcastle pharmacy experts work with Italian biotech lab to provide access to sight-saving treatment across England
- Holostem Terapie Avanzate begins its transition to a Foundation
- Transgenic Epidermal Cultures for Junctional Epidermolysis Bullosa — 5-Year Outcomes
- Gene therapy for butterfly children: 5-year follow-up published in the New England Journal of Medicine
- Hologene 5: A Phase II/III Clinical Trial of Combined Cell and Gene Therapy of Junctional Epidermolysis Bullosa